Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination consists of 1 gram of corn oil and 4 mg of alpha-tocopherol (vitamin E), formulated as a gelatin capsule for oral administration. It was utilized as the placebo control arm in the OFAMI (Omacor Following Acute Myocardial Infarction) study, conducted by Helse Stavanger HF (formerly Central Hospital in Rogaland). The corn oil provides a source of omega-6 fatty acids, while the alpha-tocopherol serves as an antioxidant to protect the polyunsaturated fats from oxidation. The formulation was designed to match the appearance and administration of Omacor (omega-3 acid ethyl esters) to maintain blinding in clinical trials investigating the secondary prevention of cardiac events in post-myocardial infarction patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on corn oil + alpha-tocopherol.